{
  "symbol": "NMTC",
  "company_name": "Neuroone Medical Technologies Corp",
  "ir_website": "https://nmtc1.com/investors",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://nmtc1.com/press.html",
          "content": "[ ![logo](assets/images/logo.png) ](/)\n\n  * [ Terms & Conditions ](terms-of-service.html)\n  * [ Privacy Policy ](privacy-policy.html)\n\n\n\n# Press Releases/News\n\nNeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.\n\n![](assets/images/investors/intro.jpg)\n\nPress Releases/News\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n## **Press Releases/News**\n\n  * [Press Releases](press.html)\n  * [News](news.html)\n  * [Events](events.html)\n  * [Presentations](presentations.html)\n  * [Video](video.html)\n\n\n\n## Better health made **attainable.**\n\n[ Get **in touch** ](contact.html)\n\n![](assets/images/about/person-1.jpg)\n\n![](assets/images/about/person-1.jpg)\n\nDAVE ROSA\n\nPresident & Chief Executive Officer\n\nMr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.\n\n![](assets/images/about/person-2.jpg)\n\n![](assets/images/about/person-2.jpg)\n\nRON McCLURG\n\nChief Financial Officer\n\nMr. McClurg has over 30 years of financial leadership experience with private and public companies. Prior to joining NeuroOne, Mr. McClurg was VP - Finance & Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments for the semiconductor industry. Mr. McClurg also served as Chief Financial Officer for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves as a director for a privately held company. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin – Eau Claire.\n\n![](assets/images/about/person-3.jpg)\n\n![](assets/images/about/person-3.jpg)\n\nMARK CHRISTIANSON\n\nCo-Founder, Business Development Director, Medical Sales Liaison\n\nIn excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.\n\n![](assets/images/about/person-4.jpg)\n\n![](assets/images/about/person-4.jpg)\n\nSTEVE MERTENS\n\nChief Technology Officer\n\nPrior to joining NeuroOne, Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, Mertens was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets.\n\nMertens began his medical device career working in engineering, quality control, and manufacturing roles at SciMed Life Sciences. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas.\n\n![](assets/images/about/Chris_nmtc.png)\n\n![](assets/images/about/Chris_nmtc.png)\n\nChris Volker\n\nChief Operating Officer\n\nMr. Volker has over 20 years of experience in the medtech industry including at Abbott, Cardiovascular Systems, Inc. (CSI), St. Jude Medical and in investment banking. At CSI, Mr. Volker held the role of Vice President & General Manager of International and had direct responsibility for international commercial expansion, including Sales, Training & Education, Marketing, Business Development and Program Management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical where he led Corporate Development, Health Economics & Reimbursement and Strategic Market Research across all of St. Jude Medical's business units as well as held executive responsibilities for Human Resources for the Cardiovascular Division. He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Masters of Business Administration degree from the Wharton School at the University of Pennsylvania.\n\n![](assets/images/about/person-6.jpg)\n\n![](assets/images/about/person-6.jpg)\n\nHijaz Haris\n\nVice President of Marketing\n\nMr. Haris has more than 20 years of experience with Medtronic, the world’s largest Medical Device company. Most recently he led Global Marketing for Medtronic’s Brain Modulation business, where he helped refresh the Deep Brain Stimulation product pipeline and led the business through a period of new competitive entries, new product launches, brand refresh, and various distribution partnerships. Prior to that Hijaz held various roles of increasing responsibility across multiple business segments (Cardiac Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product and Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance). In his career with Medtronic, he has been part of new category launches and led significant commercial initiatives across multiple areas.\n\n![](assets/images/about/person-5.jpg)\n\n![](assets/images/about/person-5.jpg)\n\nCAMILO DIAZ-BOTIA\n\nDirector of Electrode Development\n\nDr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron, and Lab-on-a-Chip.\n\nMost recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.\n\nDr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings.\n\n![](assets/images/about/person-7.jpeg)\n\n![](assets/images/about/person-7.jpeg)\n\nChad Wilhelmy\n\nVice President of Quality Control and Regulatory Affairs\n\nChad Wilhelmy joined NeuroOne with 20 years of medical device experience developing, implementing, and leading quality management systems. Prior to joining NeuroOne, he held top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine Heart as the Senior Director of Quality. He has driven quality strategies from early-stage development to commercial distribution with both the FDA and Notified Body. Chad earned a Bachelor of Science degree from the University of Wisconsin - Stout in Engineering Technology with an emphasis in Quality.\n\n![](assets/images/about/directors/Buckman.png)\n\n![](assets/images/about/directors/Buckman.png)\n\nPaul Buckman\n\nChairman\n\n![](assets/images/about/directors/Mathieson.png)\n\n![](assets/images/about/directors/Mathieson.png)\n\nJeff Mathiesen\n\nDirector\n\n![](assets/images/about/directors/Rosa.png)\n\n![](assets/images/about/directors/Rosa.png)\n\nEd Andrle\n\nDirector\n\n![](assets/images/about/directors/Andrle.png)\n\n![](assets/images/about/directors/Andrle.png)\n\nDave Rosa\n\nPresident and CEO\n\n![](assets/images/about/sab/Worrell.png)\n\n![](assets/images/about/sab/Worrell.png)\n\nGreg Worrell MD, PhD\n\nChairman\n\n![](assets/images/about/sab/Van-Gompel.png)\n\n![](assets/images/about/sab/Van-Gompel.png)\n\nJamie Van Gompel, MD\n\nBoard Member\n\n![](assets/images/about/sab/Esper.png)\n\n![](assets/images/about/sab/Esper.png)\n\nGregory J Esper, MD, MBA\n\nBoard Member\n\n![](assets/images/about/sab/Williams.png)\n\n![](assets/images/about/sab/Williams.png)\n\nJustin Williams, PhD\n\nBoard Member\n\n![](assets/images/about/sab/drgross.png)\n\n![](assets/images/about/sab/drgross.png)\n\nBob Gross, MD, PhD\n\nBoard Member\n\n![](assets/images/about/sab/KipLudwig.png)\n\n![](assets/images/about/sab/KipLudwig.png)\n\nKip Ludwig, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Ludwig.png)\n\n![](assets/images/about/ai/Ludwig.png)\n\nKip Ludwig PhD\n\nChairman\n\n![](assets/images/about/ai/Patil.png)\n\n![](assets/images/about/ai/Patil.png)\n\nParag Patil MD, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Vogelstein.png)\n\n![](assets/images/about/ai/Vogelstein.png)\n\nR Jacob Vogelstein Phd\n\nBoard Member\n\n![](assets/images/about/ai/Salem.png)\n\n![](assets/images/about/ai/Salem.png)\n\nAyem M Salem MD\n\nBoard Member\n\n![](assets/images/about/ai/Welle.png)\n\n![](assets/images/about/ai/Welle.png)\n\nCristin Welle PhD\n\nBoard Member\n\n![](assets/images/about/ai/Weber.png)\n\n![](assets/images/about/ai/Weber.png)\n\nDouglas J Weber PhD\n\nBoard Member\n\n![](assets/images/about/ai/Wagenaar.png)\n\n![](assets/images/about/ai/Wagenaar.png)\n\nJoost Wageenar PhD\n\nBoard Member\n"
        }
      ]
    },
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "News",
          "url": "https://nmtc1.com/news.html",
          "content": "[ ![logo](assets/images/logo.png) ](/)\n\n  * [ Terms & Conditions ](terms-of-service.html)\n  * [ Privacy Policy ](privacy-policy.html)\n\n\n\n# Press Releases/News\n\nNeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.\n\n![](assets/images/investors/intro.jpg)\n\nPress Releases/News\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n## **Press Releases/News**\n\n  * [Press Releases](press.html)\n  * [News](news.html)\n  * [Events](events.html)\n  * [Presentations](presentations.html)\n  * [Video](video.html)\n\n\n\n###### Seeking Alpha – June 12, 2023\n\n[NeuroOne submits FDA market application for OneRF Ablation System](https://seekingalpha.com/news/3979268-neuroone-submits-fda-market-application-for-onerf-ablation-system)\n\n###### MassDevice – June 12, 2023\n\n[NeuroOne submits RF ablation system for FDA 510(k) clearance](https://www.massdevice.com/neuroone-submits-ablation-system-fda-clearance/)\n\n###### NeuroNews International – December 12, 2022\n\n[NeuroOne successfully completes feasibility study with OneRF ablation system](https://neuronewsinternational.com/neuroone-successfully-completes-feasibility-study-with-onerf-ablation-system/)\n\n###### Medical Product Outsourcing – December 8, 2022\n\n[NeuroOne Completes Feasibility Study with OneRF Ablation System](https://www.mpo-mag.com/contents/view_breaking-news/2022-12-08/neuroone-completes-feasibility-study-with-onerf-ablation-system/)\n\n###### Parkinson's News Today – December 8, 2022\n\n[NeuroOne Plans to Ask FDA to Clear RF Ablation System in New Year](https://parkinsonsnewstoday.com/news/neuroone-will-ask-fda-clear-rf-ablation-system-parkinsons-2023/)\n\n###### Medical Design Sourcing – December 6, 2022\n\n[NeuroOne completes feasibility study of OneRF ablation system](https://www.medicaldesignsourcing.com/neuroone-completes-feasibility-study-of-onerf-ablation-system/)\n\n###### MassDevice – November 30, 2022\n\n[NeuroOne begins shipping 30-day sEEG electrodes to Zimmer Biomet](https://www.massdevice.com/neuroone-ships-seeg-electrodes-zimmer-biomet/)\n\n###### FOX Business: Mornings with Maria – November 21, 2022\n\n[NeuroOne developing brain electrode to help patients with neurological diseases](https://drive.google.com/file/d/1bDapkvygcRjyEUOtYS1wwGKxOjJ_fdCr/view)\n\n###### MD+DI – November 1, 2022\n\n[NeuroOne Tried Again – And Succeeded](https://www.mddionline.com/neurological/neuroone-tried-again-and-succeeded)\n\n###### FDAnews – October 27, 2022\n\n[NeuroOne sEEG Electrode Approved for 30-Day Use](https://www.fdanews.com/articles/209954-neuroone-seeg-electrode-approved-for-30-day-use)\n\n###### Medical Device Network – October 26, 2022\n\n[FDA grants 510(k) clearance for NeuroOne's Evo sEEG Electrode technology](https://www.medicaldevice-network.com/news/fda-510k-neuroone-evo-seeg-electrode/)\n\n###### Parkinson's News Today – October 26, 2022\n\n[FDA Clears NeuroOne Evo sEEG Device for Use Up to 30 Days](https://parkinsonsnewstoday.com/news/fda-clears-neuroone-evo-seeg-device-temporary-use-brain-activity/)\n\n###### MassDevice – October 25, 2022\n\n[FDA clears NeuroOne's Evo sEEG electrode for 30-day use](https://www.massdevice.com/fda-clears-neuroones-evo-seeg-electrode-for-30-day-use/)\n\n###### Medical Product Outsourcing – October 25, 2022\n\n[FDA OKs NeuroOne's Evo sEEG for Under 30 Day Use](https://www.mpo-mag.com/contents/view_breaking-news/2022-10-25/fda-oks-neuroones-evo-seeg-for-under-30-day-use/65659)\n\n###### Today’s Medical Developments – October 14, 2022\n\n[Special 510(k) submitted to FDA for Evo sEEG Electrode](https://www.todaysmedicaldevelopments.com/article/medical-orthopedic-design-manufacturing-implants-regulatory/)\n\n###### Medical Design & Outsourcing – September 21, 2022\n\n[How NeuroOne and Zimmer Biomet will partner on robotic brain surgery](https://www.medicaldesignandoutsourcing.com/neuroone-evo-seeg-zimmer-biomet-robotic-brain-surgery/)\n\n###### Design News – August 31, 2022\n\n[Thin, Flexible Electrode May Reduce Hospitalizations and Surgeries](https://www.designnews.com/medical/thin-flexible-electrode-may-reduce-hospitalizations-and-surgeries)\n\n###### Nasdaq – August 9, 2022\n\n[NeuroOne Re-submits Application For SEEG Electrode To Extend Duration Of Use](https://www.nasdaq.com/articles/neuroone-re-submits-application-for-seeg-electrode-to-extend-duration-of-use)\n\n###### Seeking Alpha – August 3, 2022\n\n[NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet](https://seekingalpha.com/news/3865812-neuroone-rallies-on-receiving-35m-in-accelerated-milestone-payment-from-zimmer-biomet)\n\n###### MergerMarket – August 2, 2022\n\n[NeuroOne may consider partnerships next year with FDA clearance, CEO says](https://drive.google.com/file/d/1r47QINEj8Iko88iJYOb9yyIInV2xFW1B/view?usp=sharing)\n\n###### MedTech Insight – July 13, 2022\n\n[NeuroOne: Thinner Is Better When It Comes To Brain Electrodes](https://medtech.pharmaintelligence.informa.com/MT145607/NeuroOne-Thinner-Is-Better-When-It-Comes-To-Brain-Electrodes)\n\n###### MassDevice – July 12, 2022\n\n[NeuroOne announces first clinical case using Evo sEEG electrodes](https://www.massdevice.com/neuroone-announces-first-clinical-case-using-evo-seeg-electrodes/)\n\n###### MedGadget – June 1, 2022\n\n[Thin Film Electrodes for Neuro Applications: Interview with Dave Rosa, CEO of NeuroOne](https://www.medgadget.com/2022/06/thin-film-electrodes-for-neuro-applications-interview-with-dave-rosa-ceo-of-neuroone.html)\n\n###### Empowered Patient Podcast – April 14, 2022\n\n[Thin-Film High-Resolution Electrode Technology Driving Advancements in Neurosurgery: Interview with NeuroOne CEO Dave Rosa](https://empoweredpatientradio.com/thin-film-high-resolution-electrode-technologydriving-advancements-in-neurosurgery-with-dave-rosa-neuroone)\n\n###### MD+DI – March 29, 2022\n\n[NeuroOne Achieves Milestone for Thin Film Electrode Technology](https://www.mddionline.com/components/neuroone-achieves-milestone-thin-film-electrode-technology)\n\n###### The Fly – March 7, 2022\n\n[Meet NeuroOne: Fly exclusive interview with CEO Dave Rosa](https://thefly.com/landingPageNews.php?id=3472893&headline=NMTC-Meet-NeuroOne-Fly-exclusive-interview-with-CEO-Dave-Rosa)\n\n###### BioWorld MedTech – March 3, 2022\n\n[Neuroone touts longevity stimulation data for electrode film tech](https://www.bioworld.com/articles/516641-neuroone-touts-longevity-stimulation-data-for-electrode-film-tech?v=preview)\n\n###### FOX Business: The Claman Countdown – February 11, 2022\n\n[NeuroOne's next-generation electrodes to treat neurological disorders](https://video.foxbusiness.com/v/6297041848001#sp=show-clips)\n\n###### Medical Design & Outsourcing – February 9, 2022\n\n[NeuroOne reports successful durability tests of thin-film electrodes](https://www.medicaldesignandoutsourcing.com/neuroone-thin-film-electrodes-durability-test/)\n\n###### Medical Product Outsourcing – February 9, 2022\n\n[NeuroOne completes initial pre-clinical testing of its thin film electrode technology](https://www.mpo-mag.com/contents/view_breaking-news/2022-02-09/neuroone-completes-initial-pre-clinical-testing-of-its-thin-film-electrode-technology/)\n\n###### MedCity News – January 21, 2022\n\n[NeuroOne appoints Vice President of Quality Control and Regulatory Affairs](https://medcitynews.com/2022/01/startupdates-new-developments-from-healthcare-startups-53/)\n\n###### Benzinga Live – January 4, 2022\n\n[Interview with NeuroOne CEO Dave Rosa](https://drive.google.com/file/d/19dzHwWC5oWnVYb8D14QReShVC9fLjQtY/view?usp=sharing)\n\n###### Minneapolis / St. Paul Business Journal – December 14, 2021\n\n[NeuroOne CEO Dave Rosa talks uplisting on Nasdaq, upcoming advancements](https://www.bizjournals.com/twincities/inno/stories/news/2021/12/14/neuroone-ceo-dave-rosa.html)\n\n###### The Medical Alley Podcast – December 13, 2021\n\n[A Conversation with Dave Rosa, President and CEO of NeuroOne](https://medicalalleypodcast.org/episodes/a-conversation-with-dave-rosa-president-and-ceo-neuroone)\n\n###### Medical Product Outsourcing – December 8, 2021\n\n[FDA clears NeuroOne Medical Technologies' Evo sEEG electrode](https://www.mpo-mag.com/contents/view_breaking-news/2021-12-08/fda-clears-neuroone-medical-technologies-evo-seeg-electrode/?widget=listSection)\n\n###### NeuroNews International – September 23, 2021\n\n[NeuroOne successfully completes feasibility study of Evo ablation electrode](https://neuronewsinternational.com/neuroone-successfully-completes-feasibility-study-of-evo-ablation-electrode/)\n\n###### MassDevice – September 13, 2021\n\n[FDA clears NeuroOne's Evo sEEG electrode](https://www.massdevice.com/fda-clears-neuroones-evo-seeg-electrode/)\n\n###### Medical Design & Outsourcing – September 13, 2021\n\n[FDA clears NeuroOne's Evo sEEG electrode](https://www.medicaldesignandoutsourcing.com/fda-clears-neuroones-evo-seeg-electrode/)\n\n###### Cheddar News – August 18, 2021\n\n[Advancements in neuroscience](https://cheddar.com/media/can-this-brain-implant-save-lives)\n\n###### Minneapolis / St. Paul Business Journal – May 27, 2021\n\n[Epilepsy tech company NeuroOne starts trading on the Nasdaq](https://www.bizjournals.com/twincities/news/2021/05/27/epilepsy-tech-company-neuroone.html)\n\n###### Medical Design Briefs – September 1, 2020\n\n[Thin film electrodes show potential for transforming neurosurgery](https://www.medicaldesignbriefs.com/component/content/article/mdb/features/technology-leaders/37594)\n\n###### BioWorld – August 20, 2020\n\n[NeuroOne thin film electrode technology enables extended, minimally invasive device](https://www.bioworld.com/articles/497012-neuroone-thin-film-electrode-technology-enables-extended-minimally-invasive-device?v=preview)\n\n###### BioTuesdays – July 14, 2020\n\n[NeuroOne developing electrode technology to treat neurological conditions](https://biotuesdays.com/2020/07/14/neuroone-developing-electrode-technology-to-treat-neurological-conditions/)\n\n###### Medical Product Outsourcing – June 20, 2020\n\n[Thin-film electrodes for brain surgery reach the market](https://www.mpo-mag.com/contents/view_online-exclusives/2020-06-30/thin-film-electrodes-for-brain-surgery-reach-the-market/)\n\n## Better health made **attainable.**\n\n[ Get **in touch** ](contact.html)\n\n![](assets/images/about/person-1.jpg)\n\n![](assets/images/about/person-1.jpg)\n\nDAVE ROSA\n\nPresident & Chief Executive Officer\n\nMr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.\n\n![](assets/images/about/person-2.jpg)\n\n![](assets/images/about/person-2.jpg)\n\nRON McCLURG\n\nChief Financial Officer\n\nMr. McClurg has over 30 years of financial leadership experience with private and public companies. Prior to joining NeuroOne, Mr. McClurg was VP - Finance & Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments for the semiconductor industry. Mr. McClurg also served as Chief Financial Officer for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves as a director for a privately held company. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin – Eau Claire.\n\n![](assets/images/about/person-3.jpg)\n\n![](assets/images/about/person-3.jpg)\n\nMARK CHRISTIANSON\n\nCo-Founder, Business Development Director, Medical Sales Liaison\n\nIn excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.\n\n![](assets/images/about/person-4.jpg)\n\n![](assets/images/about/person-4.jpg)\n\nSTEVE MERTENS\n\nChief Technology Officer\n\nPrior to joining NeuroOne, Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, Mertens was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets.\n\nMertens began his medical device career working in engineering, quality control, and manufacturing roles at SciMed Life Sciences. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas.\n\n![](assets/images/about/Chris_nmtc.png)\n\n![](assets/images/about/Chris_nmtc.png)\n\nChris Volker\n\nChief Operating Officer\n\nMr. Volker has over 20 years of experience in the medtech industry including at Abbott, Cardiovascular Systems, Inc. (CSI), St. Jude Medical and in investment banking. At CSI, Mr. Volker held the role of Vice President & General Manager of International and had direct responsibility for international commercial expansion, including Sales, Training & Education, Marketing, Business Development and Program Management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical where he led Corporate Development, Health Economics & Reimbursement and Strategic Market Research across all of St. Jude Medical's business units as well as held executive responsibilities for Human Resources for the Cardiovascular Division. He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Masters of Business Administration degree from the Wharton School at the University of Pennsylvania.\n\n![](assets/images/about/person-6.jpg)\n\n![](assets/images/about/person-6.jpg)\n\nHijaz Haris\n\nVice President of Marketing\n\nMr. Haris has more than 20 years of experience with Medtronic, the world’s largest Medical Device company. Most recently he led Global Marketing for Medtronic’s Brain Modulation business, where he helped refresh the Deep Brain Stimulation product pipeline and led the business through a period of new competitive entries, new product launches, brand refresh, and various distribution partnerships. Prior to that Hijaz held various roles of increasing responsibility across multiple business segments (Cardiac Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product and Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance). In his career with Medtronic, he has been part of new category launches and led significant commercial initiatives across multiple areas.\n\n![](assets/images/about/person-5.jpg)\n\n![](assets/images/about/person-5.jpg)\n\nCAMILO DIAZ-BOTIA\n\nDirector of Electrode Development\n\nDr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron, and Lab-on-a-Chip.\n\nMost recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.\n\nDr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings.\n\n![](assets/images/about/person-7.jpeg)\n\n![](assets/images/about/person-7.jpeg)\n\nChad Wilhelmy\n\nVice President of Quality Control and Regulatory Affairs\n\nChad Wilhelmy joined NeuroOne with 20 years of medical device experience developing, implementing, and leading quality management systems. Prior to joining NeuroOne, he held top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine Heart as the Senior Director of Quality. He has driven quality strategies from early-stage development to commercial distribution with both the FDA and Notified Body. Chad earned a Bachelor of Science degree from the University of Wisconsin - Stout in Engineering Technology with an emphasis in Quality.\n\n![](assets/images/about/directors/Buckman.png)\n\n![](assets/images/about/directors/Buckman.png)\n\nPaul Buckman\n\nChairman\n\n![](assets/images/about/directors/Mathieson.png)\n\n![](assets/images/about/directors/Mathieson.png)\n\nJeff Mathiesen\n\nDirector\n\n![](assets/images/about/directors/Rosa.png)\n\n![](assets/images/about/directors/Rosa.png)\n\nEd Andrle\n\nDirector\n\n![](assets/images/about/directors/Andrle.png)\n\n![](assets/images/about/directors/Andrle.png)\n\nDave Rosa\n\nPresident and CEO\n\n![](assets/images/about/sab/Worrell.png)\n\n![](assets/images/about/sab/Worrell.png)\n\nGreg Worrell MD, PhD\n\nChairman\n\n![](assets/images/about/sab/Van-Gompel.png)\n\n![](assets/images/about/sab/Van-Gompel.png)\n\nJamie Van Gompel, MD\n\nBoard Member\n\n![](assets/images/about/sab/Esper.png)\n\n![](assets/images/about/sab/Esper.png)\n\nGregory J Esper, MD, MBA\n\nBoard Member\n\n![](assets/images/about/sab/Williams.png)\n\n![](assets/images/about/sab/Williams.png)\n\nJustin Williams, PhD\n\nBoard Member\n\n![](assets/images/about/sab/drgross.png)\n\n![](assets/images/about/sab/drgross.png)\n\nBob Gross, MD, PhD\n\nBoard Member\n\n![](assets/images/about/sab/KipLudwig.png)\n\n![](assets/images/about/sab/KipLudwig.png)\n\nKip Ludwig, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Ludwig.png)\n\n![](assets/images/about/ai/Ludwig.png)\n\nKip Ludwig PhD\n\nChairman\n\n![](assets/images/about/ai/Patil.png)\n\n![](assets/images/about/ai/Patil.png)\n\nParag Patil MD, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Vogelstein.png)\n\n![](assets/images/about/ai/Vogelstein.png)\n\nR Jacob Vogelstein Phd\n\nBoard Member\n\n![](assets/images/about/ai/Salem.png)\n\n![](assets/images/about/ai/Salem.png)\n\nAyem M Salem MD\n\nBoard Member\n\n![](assets/images/about/ai/Welle.png)\n\n![](assets/images/about/ai/Welle.png)\n\nCristin Welle PhD\n\nBoard Member\n\n![](assets/images/about/ai/Weber.png)\n\n![](assets/images/about/ai/Weber.png)\n\nDouglas J Weber PhD\n\nBoard Member\n\n![](assets/images/about/ai/Wagenaar.png)\n\n![](assets/images/about/ai/Wagenaar.png)\n\nJoost Wageenar PhD\n\nBoard Member\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://nmtc1.com/sec-filings.html",
          "content": "[ ![logo](assets/images/logo.png) ](/)\n\n  * [ Terms & Conditions ](terms-of-service.html)\n  * [ Privacy Policy ](privacy-policy.html)\n\n\n\n# SEC Filings\n\nNeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.\n\n![](assets/images/investors/intro.jpg)\n\nSEC Filings\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n## Better health made **attainable.**\n\n[ Get **in touch** ](contact.html)\n\n![](assets/images/about/person-1.jpg)\n\n![](assets/images/about/person-1.jpg)\n\nDAVE ROSA\n\nPresident & Chief Executive Officer\n\nMr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.\n\n![](assets/images/about/person-2.jpg)\n\n![](assets/images/about/person-2.jpg)\n\nRON McCLURG\n\nChief Financial Officer\n\nMr. McClurg has over 30 years of financial leadership experience with private and public companies. Prior to joining NeuroOne, Mr. McClurg was VP - Finance & Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments for the semiconductor industry. Mr. McClurg also served as Chief Financial Officer for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves as a director for a privately held company. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin – Eau Claire.\n\n![](assets/images/about/person-3.jpg)\n\n![](assets/images/about/person-3.jpg)\n\nMARK CHRISTIANSON\n\nCo-Founder, Business Development Director, Medical Sales Liaison\n\nIn excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.\n\n![](assets/images/about/person-4.jpg)\n\n![](assets/images/about/person-4.jpg)\n\nSTEVE MERTENS\n\nChief Technology Officer\n\nPrior to joining NeuroOne, Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, Mertens was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets.\n\nMertens began his medical device career working in engineering, quality control, and manufacturing roles at SciMed Life Sciences. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas.\n\n![](assets/images/about/Chris_nmtc.png)\n\n![](assets/images/about/Chris_nmtc.png)\n\nChris Volker\n\nChief Operating Officer\n\nMr. Volker has over 20 years of experience in the medtech industry including at Abbott, Cardiovascular Systems, Inc. (CSI), St. Jude Medical and in investment banking. At CSI, Mr. Volker held the role of Vice President & General Manager of International and had direct responsibility for international commercial expansion, including Sales, Training & Education, Marketing, Business Development and Program Management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical where he led Corporate Development, Health Economics & Reimbursement and Strategic Market Research across all of St. Jude Medical's business units as well as held executive responsibilities for Human Resources for the Cardiovascular Division. He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Masters of Business Administration degree from the Wharton School at the University of Pennsylvania.\n\n![](assets/images/about/person-6.jpg)\n\n![](assets/images/about/person-6.jpg)\n\nHijaz Haris\n\nVice President of Marketing\n\nMr. Haris has more than 20 years of experience with Medtronic, the world’s largest Medical Device company. Most recently he led Global Marketing for Medtronic’s Brain Modulation business, where he helped refresh the Deep Brain Stimulation product pipeline and led the business through a period of new competitive entries, new product launches, brand refresh, and various distribution partnerships. Prior to that Hijaz held various roles of increasing responsibility across multiple business segments (Cardiac Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product and Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance). In his career with Medtronic, he has been part of new category launches and led significant commercial initiatives across multiple areas.\n\n![](assets/images/about/person-5.jpg)\n\n![](assets/images/about/person-5.jpg)\n\nCAMILO DIAZ-BOTIA\n\nDirector of Electrode Development\n\nDr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron, and Lab-on-a-Chip.\n\nMost recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.\n\nDr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings.\n\n![](assets/images/about/person-7.jpeg)\n\n![](assets/images/about/person-7.jpeg)\n\nChad Wilhelmy\n\nVice President of Quality Control and Regulatory Affairs\n\nChad Wilhelmy joined NeuroOne with 20 years of medical device experience developing, implementing, and leading quality management systems. Prior to joining NeuroOne, he held top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine Heart as the Senior Director of Quality. He has driven quality strategies from early-stage development to commercial distribution with both the FDA and Notified Body. Chad earned a Bachelor of Science degree from the University of Wisconsin - Stout in Engineering Technology with an emphasis in Quality.\n\n![](assets/images/about/directors/Buckman.png)\n\n![](assets/images/about/directors/Buckman.png)\n\nPaul Buckman\n\nChairman\n\n![](assets/images/about/directors/Mathieson.png)\n\n![](assets/images/about/directors/Mathieson.png)\n\nJeff Mathiesen\n\nDirector\n\n![](assets/images/about/directors/Rosa.png)\n\n![](assets/images/about/directors/Rosa.png)\n\nEd Andrle\n\nDirector\n\n![](assets/images/about/directors/Andrle.png)\n\n![](assets/images/about/directors/Andrle.png)\n\nDave Rosa\n\nPresident and CEO\n\n![](assets/images/about/sab/Worrell.png)\n\n![](assets/images/about/sab/Worrell.png)\n\nGreg Worrell MD, PhD\n\nChairman\n\n![](assets/images/about/sab/Van-Gompel.png)\n\n![](assets/images/about/sab/Van-Gompel.png)\n\nJamie Van Gompel, MD\n\nBoard Member\n\n![](assets/images/about/sab/Esper.png)\n\n![](assets/images/about/sab/Esper.png)\n\nGregory J Esper, MD, MBA\n\nBoard Member\n\n![](assets/images/about/sab/Williams.png)\n\n![](assets/images/about/sab/Williams.png)\n\nJustin Williams, PhD\n\nBoard Member\n\n![](assets/images/about/sab/drgross.png)\n\n![](assets/images/about/sab/drgross.png)\n\nBob Gross, MD, PhD\n\nBoard Member\n\n![](assets/images/about/sab/KipLudwig.png)\n\n![](assets/images/about/sab/KipLudwig.png)\n\nKip Ludwig, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Ludwig.png)\n\n![](assets/images/about/ai/Ludwig.png)\n\nKip Ludwig PhD\n\nChairman\n\n![](assets/images/about/ai/Patil.png)\n\n![](assets/images/about/ai/Patil.png)\n\nParag Patil MD, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Vogelstein.png)\n\n![](assets/images/about/ai/Vogelstein.png)\n\nR Jacob Vogelstein Phd\n\nBoard Member\n\n![](assets/images/about/ai/Salem.png)\n\n![](assets/images/about/ai/Salem.png)\n\nAyem M Salem MD\n\nBoard Member\n\n![](assets/images/about/ai/Welle.png)\n\n![](assets/images/about/ai/Welle.png)\n\nCristin Welle PhD\n\nBoard Member\n\n![](assets/images/about/ai/Weber.png)\n\n![](assets/images/about/ai/Weber.png)\n\nDouglas J Weber PhD\n\nBoard Member\n\n![](assets/images/about/ai/Wagenaar.png)\n\n![](assets/images/about/ai/Wagenaar.png)\n\nJoost Wageenar PhD\n\nBoard Member\n"
        },
        {
          "title": "Stock Data",
          "url": "https://nmtc1.com/charts.html",
          "content": "[ ![logo](assets/images/logo.png) ](/)\n\n  * [ Terms & Conditions ](terms-of-service.html)\n  * [ Privacy Policy ](privacy-policy.html)\n\n\n\n# Stock Data\n\nNeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.\n\n![](assets/images/investors/intro.jpg)\n\nStock Data\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n  * [Overview](investors.html)\n  * [Press Releases/News](press.html)\n  * [Stock Data](charts.html)\n  * [SEC Filings](sec-filings.html)\n  * [Governance](governance.html)\n  * [Email Alerts](alerts.html)\n\n\n\n## **Stock Data**\n\n  * [Charts](charts.html)\n\n\n\n## Better health made **attainable.**\n\n[ Get **in touch** ](contact.html)\n\n![](assets/images/about/person-1.jpg)\n\n![](assets/images/about/person-1.jpg)\n\nDAVE ROSA\n\nPresident & Chief Executive Officer\n\nMr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.\n\n![](assets/images/about/person-2.jpg)\n\n![](assets/images/about/person-2.jpg)\n\nRON McCLURG\n\nChief Financial Officer\n\nMr. McClurg has over 30 years of financial leadership experience with private and public companies. Prior to joining NeuroOne, Mr. McClurg was VP - Finance & Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments for the semiconductor industry. Mr. McClurg also served as Chief Financial Officer for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves as a director for a privately held company. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin – Eau Claire.\n\n![](assets/images/about/person-3.jpg)\n\n![](assets/images/about/person-3.jpg)\n\nMARK CHRISTIANSON\n\nCo-Founder, Business Development Director, Medical Sales Liaison\n\nIn excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.\n\n![](assets/images/about/person-4.jpg)\n\n![](assets/images/about/person-4.jpg)\n\nSTEVE MERTENS\n\nChief Technology Officer\n\nPrior to joining NeuroOne, Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, Mertens was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets.\n\nMertens began his medical device career working in engineering, quality control, and manufacturing roles at SciMed Life Sciences. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas.\n\n![](assets/images/about/Chris_nmtc.png)\n\n![](assets/images/about/Chris_nmtc.png)\n\nChris Volker\n\nChief Operating Officer\n\nMr. Volker has over 20 years of experience in the medtech industry including at Abbott, Cardiovascular Systems, Inc. (CSI), St. Jude Medical and in investment banking. At CSI, Mr. Volker held the role of Vice President & General Manager of International and had direct responsibility for international commercial expansion, including Sales, Training & Education, Marketing, Business Development and Program Management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical where he led Corporate Development, Health Economics & Reimbursement and Strategic Market Research across all of St. Jude Medical's business units as well as held executive responsibilities for Human Resources for the Cardiovascular Division. He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Masters of Business Administration degree from the Wharton School at the University of Pennsylvania.\n\n![](assets/images/about/person-6.jpg)\n\n![](assets/images/about/person-6.jpg)\n\nHijaz Haris\n\nVice President of Marketing\n\nMr. Haris has more than 20 years of experience with Medtronic, the world’s largest Medical Device company. Most recently he led Global Marketing for Medtronic’s Brain Modulation business, where he helped refresh the Deep Brain Stimulation product pipeline and led the business through a period of new competitive entries, new product launches, brand refresh, and various distribution partnerships. Prior to that Hijaz held various roles of increasing responsibility across multiple business segments (Cardiac Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product and Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance). In his career with Medtronic, he has been part of new category launches and led significant commercial initiatives across multiple areas.\n\n![](assets/images/about/person-5.jpg)\n\n![](assets/images/about/person-5.jpg)\n\nCAMILO DIAZ-BOTIA\n\nDirector of Electrode Development\n\nDr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron, and Lab-on-a-Chip.\n\nMost recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.\n\nDr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings.\n\n![](assets/images/about/person-7.jpeg)\n\n![](assets/images/about/person-7.jpeg)\n\nChad Wilhelmy\n\nVice President of Quality Control and Regulatory Affairs\n\nChad Wilhelmy joined NeuroOne with 20 years of medical device experience developing, implementing, and leading quality management systems. Prior to joining NeuroOne, he held top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine Heart as the Senior Director of Quality. He has driven quality strategies from early-stage development to commercial distribution with both the FDA and Notified Body. Chad earned a Bachelor of Science degree from the University of Wisconsin - Stout in Engineering Technology with an emphasis in Quality.\n\n![](assets/images/about/directors/Buckman.png)\n\n![](assets/images/about/directors/Buckman.png)\n\nPaul Buckman\n\nChairman\n\n![](assets/images/about/directors/Mathieson.png)\n\n![](assets/images/about/directors/Mathieson.png)\n\nJeff Mathiesen\n\nDirector\n\n![](assets/images/about/directors/Rosa.png)\n\n![](assets/images/about/directors/Rosa.png)\n\nEd Andrle\n\nDirector\n\n![](assets/images/about/directors/Andrle.png)\n\n![](assets/images/about/directors/Andrle.png)\n\nDave Rosa\n\nPresident and CEO\n\n![](assets/images/about/sab/Worrell.png)\n\n![](assets/images/about/sab/Worrell.png)\n\nGreg Worrell MD, PhD\n\nChairman\n\n![](assets/images/about/sab/Van-Gompel.png)\n\n![](assets/images/about/sab/Van-Gompel.png)\n\nJamie Van Gompel, MD\n\nBoard Member\n\n![](assets/images/about/sab/Esper.png)\n\n![](assets/images/about/sab/Esper.png)\n\nGregory J Esper, MD, MBA\n\nBoard Member\n\n![](assets/images/about/sab/Williams.png)\n\n![](assets/images/about/sab/Williams.png)\n\nJustin Williams, PhD\n\nBoard Member\n\n![](assets/images/about/sab/drgross.png)\n\n![](assets/images/about/sab/drgross.png)\n\nBob Gross, MD, PhD\n\nBoard Member\n\n![](assets/images/about/sab/KipLudwig.png)\n\n![](assets/images/about/sab/KipLudwig.png)\n\nKip Ludwig, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Ludwig.png)\n\n![](assets/images/about/ai/Ludwig.png)\n\nKip Ludwig PhD\n\nChairman\n\n![](assets/images/about/ai/Patil.png)\n\n![](assets/images/about/ai/Patil.png)\n\nParag Patil MD, PhD\n\nBoard Member\n\n![](assets/images/about/ai/Vogelstein.png)\n\n![](assets/images/about/ai/Vogelstein.png)\n\nR Jacob Vogelstein Phd\n\nBoard Member\n\n![](assets/images/about/ai/Salem.png)\n\n![](assets/images/about/ai/Salem.png)\n\nAyem M Salem MD\n\nBoard Member\n\n![](assets/images/about/ai/Welle.png)\n\n![](assets/images/about/ai/Welle.png)\n\nCristin Welle PhD\n\nBoard Member\n\n![](assets/images/about/ai/Weber.png)\n\n![](assets/images/about/ai/Weber.png)\n\nDouglas J Weber PhD\n\nBoard Member\n\n![](assets/images/about/ai/Wagenaar.png)\n\n![](assets/images/about/ai/Wagenaar.png)\n\nJoost Wageenar PhD\n\nBoard Member\n"
        }
      ]
    },
    {
      "section_name": "Investor Documents",
      "links": [
        {
          "title": "Investor Presentation",
          "url": "https://storage.googleapis.com/neuroone-1156-4b1gd/NeuroOne%20Investor%20Presentation%20Nov%202023.pdf",
          "content": "NeuroOne® Medical Technologies Corporation\nNASDAQ: NMTC May 2023\nForward-Looking Statements\nThis presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,\nas amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne's current views about future\nevents. In some cases, you can identify forward–looking statements by the words \"may,\" \"might,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"upcoming,\" \"target,\" \"objective,\"\n\"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\" \"target,\" \"seek,\" \"contemplate,\" \"continue\" and \"ongoing,\" or the negative of these terms, or other comparable terminology.\nForward–looking statements may include statements regarding the development of the Company's ablation electrode technology program, applications for, or receipt of, regulatory\nclearance, the timing and extent of product launch and commercialization of our technology, expected milestone payments, clinical and pre-clinical testing, what the future may hold for\nelectrical stimulation and NeuroOne's potential role, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating\ninformation. Our actual future results may be materially different from what we expect due to known and unknown risks, uncertainties and other factors that may cause our actual results,\nlevels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks that the partnership\nwith Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely\nmanner or at all, whether due to supply chain disruptions and the impact of COVID-19, or otherwise; risks that our technology will not perform as expected based on results of our pre-\nclinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds; the risk that\nthe COVID-19 pandemic will continue to adversely impact our business; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology;\nuncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have\naccurately estimated the size and growth potential of the markets for our technology; risks related to clinical trial patient enrollment and the results of clinical trials; that we may be unable\nto protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading \"Risk Factors\" in our filings with the Securities and\nExchange Commission. These forward–looking statements speak only as of the date of this presentation and NeuroOne undertakes no obligation to revise or update any forward–looking\nstatements for any reason, even if new information becomes available in the future.\nThis presentation also contains estimates and other statistical data made by independent parties and by us relating to market share and other data about our industry. This data involves a\nnumber of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.\nThe trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.\nCaution: Federal law restricts this device to sale by or on the order of a physician\n2\nInvestment Highlights\nOur Goal\nMedical technology developer of best-in-class electrodes designed to diagnose and treat\ndebilitating neurological conditions; Multi-Billion market opportunity for combination devices1\nMarketing and distribution partnership with Zimmer Biomet for diagnostic applications;\nAnticipated launch of EVO® Cortical/EVO® sEEG electrodes in late Q1 20232 ($100M+ Market3)\nPlanned U.S. regulatory submission (510k) of OneRF® Ablation system in Q2 2023; for use with\nEVO sEEG® electrodes to treat neurologic conditions\nStrategy to access the ablation market through additional partnerships leveraging the resources\nof commercial med tech companies; Zimmer has rights of first negotiation\nNext-generation electrodes in development for spinal cord & deep brain stimulation to treat\nchronic conditions such as Parkinson’s disease, epilepsy, tremors, chronic pain\nCash runway to achieve meaningful inflection points\n1) Market opportunity derived from combination of diagnostic and therapeutic device TAMs (Total Addressable Markets)\n3 2) Bower R, et al. December 2017. Development of Polyimide electrodes for high-resolution intracranial EEG recordings. (Abst. 1.060) American Epilepsy Society. Washington, D.C.\n3) NeuroOne Estimate based on various research reports for US cortical and sEEG diagnostic market only\nNeurological Disorders - The\nNext Frontier In Medicine\nSignificant Need: Addressing\nCurrent Treatment Challenges:\n“Neuroscience is the next great frontier in medicine”\nElectrodes are used to:\n“I think we’re on the cusp of some major breakthroughs in this space”\n• Detect, record and monitor\nCasper Hoogenraad, Genentech (VP, Neuroscience) June 2021 neurological activity\n• Stimulate or ablate tissue to\n▪ Growing epidemic of neurological disorders: epilepsy,\nregulate brain activity\nParkinson’s Disease, chronic back pain, depression, essential\nOne RF Ablation system may offer:\ntremors etc.\n• Detection, recording, and\ntreatment in one procedure\n▪ Lack of innovation in electrode technology has slowed\n• ↑ patient satisfaction\ninsights and progress toward better treatment alternatives\n• Lower patient risk\n• Lower cost\n▪ NeuroOne has developed a breakthrough thin-film electrode\n• Improved accuracy\n4\nElectrode Technology Value Proposition\nHighly Disruptive Thin-Film Technology with Superior Competitive Advantages\n▪ Highly flexible design provides new options for surgical placement and potentially\nThin-Film &\nsmaller borings/incisions\nFlexibility\n▪ Lower inflammation compared to bulkier electrodes2\n▪ Enables pairing of diagnostic and therapeutic into combination product\nCombination\n▪ Potential to be used in an MRI machine - current electrodes can’t be used in MRI\nDevice\n▪ Potential to eliminate an entire surgical procedure and improve outcomes\n▪ Ultra High-definition technology increases signal clarity via lower impedance1 (noise)\nPrecision\n▪ May enable ablation or stimulation of the targeted tissue with better precision\n▪ May have ability to detect micro-seizures2 and treat prior to seizure progression\n▪ Cost competitive to current electrode technology\nCost &\n▪ Fast fulfillment – automated / scalable process\nManufacturing\n▪ High reliability – no soldering / consistent manufacturing process\n5 1) Bower R, et al. December 2017. Multi-Resolution intracranial EEG rodent recording system.(Abst. 2.062) 2017. American Epilepsy Society\n2) Worrell G A et al. COMMERCIAL SCALE PRODUCTION OF THIN-FILM ELECTRODE ARRAYS FOR CLINICAL INTRACRANIAL EEG AES abstracts (Abst. 1.154), 2019\nDiagnostic\nEvo® Cortical Electrode\n3 Applications\n▪ Epilepsy surgery\nGreater Precision\n▪ Intraoperative mapping\nThe single substrate allows for lower impedance to improve signal quality. 1\nContact size and shape of electrodes may be customizable per neurosurgeon’s request in the\nfuture.\nCompetitors\nThin Film Design ▪ Ad-Tech ▪ Integra\nThe thin film, flexible design provides new options for surgical placement. ▪ PMT ▪ Cortec\nSingle thin tail has less bulk while tunneling through the scalp and less incisions for\npossible infections.\nDisposable Cables\nDisposable cables eliminate the need to sterilize cables and saves the surgical staff time,\nallowing them to focus on other important tasks.\nDisposable cables save the hospital resources by not having staff manage the sterilization\nof electrode cables.\nClinical Evidence\nStudy conducted by the Mayo Clinic found our electrodes created less tissue inflammation\non the brain after being implanted for 7 days. 2\n1) Worrell G A et al. COMMERCIAL SCALE PRODUCTION OF THIN-FILM ELECTRODE ARRAYS FOR CLINICAL INTRACRANIAL EEG AES abstracts (Abst. 1.154), 2019\n6\n2) Bower R, et al. December 2017. Development of Polyimide electrodes for high-resolution intracranial EEG recordings. (Abst. 1.060) American Epilepsy Society. Washington, D.C\n3) In November 2019, we received 510(k) clearance for our Evo Cortical Electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain\nDiagnostic\nMarket > $100M1\nThin-Film\nApplications\nDepth Electrode\n▪ Epilepsy surgery\n▪ Awake Brain\nCan be used in Combination with ROSA ONE®\nMapping\nProcedures\nNeuroOne Potential Advantages:\nCompetitors\n▪ Increase signal clarity / reduced noise.\n▪ Ad-Tech ▪ Integra\n▪ Better tactile feedback during insertion into brain tissue\n▪ Faster order fulfillment due to manufacturing ▪ PMT ▪ DIXI\nprocess.\nProduct Development/Commercial Launch:\n▪ FDA 510K for 24 hr. use; first case performed July 2022\n▪ Re-submitted 510(k) for < 30 day use August 2022\n▪ FDA 510(k) for < 30 day use – October 2022\nCommercial Launch –Early ‘232\nAll products are Rx only\n7 1) NeuroOne Estimate based on various research reports for US cortical and sEEG diagnostic market only\n2) Zimmer sEEG accessory regulatory clearance or internal justifications need to be complete\nZimmer Development Agreement\n▪ Zimmer is a worldwide leader in robotic technology\nused in minimally invasive neurosurgeries\n▪ Evo® electrode product line complementary to Zimmer’s\nROSA ONE® Brain platform\n▪ Agreement signed in July 2020, $2 million upfront\npayment with additional milestones\n▪ Accelerated $3.5M milestone payment made in August\n2022; Zimmer received 350,000 warrants with an exercise\nprice of $3.00/share\n▪ Zimmer to exclusively commercialize and distribute\nNeuroOne’s Evo® electrode diagnostic technology Development and Distribution\nAgreement with Zimmer\n▪ Allows NeuroOne to focus on development and pursue\nBiomet, one of the world’s\nadditional applications for technology\nmost highly respected medical\ndevice manufacturers\nEvo® sEEG electrodes represent incremental revenue\nper procedure not including other accessories\nrequired for the procedure\n8\nMayo Clinic Partnership\n▪ Mayo Clinic began testing technology in pre-clinical models\nand clinical research in 2015\n▪ Current investor\n▪ Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne\nScientific Advisory Board\n▪ First commercial human use of Evo® Cortical Electrodes performed at\nMayo Clinic in November 2020\n▪ Mayo Clinic partnership with NeuroOne began in 2017\nMayo Clinic Board Representation\nMayo Clinic serves as a critical\nGreg Worrell MD, PhD, Chairman of the Scientific Advisory Board\npartner to NeuroOne and as a\nWorld renowned neurologist at Mayo Clinic. Recognized by the American Epilepsy Society (AES), the American top shareholder of the Company\nAcademy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Research for\nEpilepsy (CURE) Foundation for his contributions to the field of epilepsy research. Dr. Worrell is a frequent keynote\nspeaker at neurology conferences and has published 90 papers.\nJamie Van Gompel, MD\nNeurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing minimally invasive techniques. Since 2008, Dr.\nVan Gompel has authored or co-authored 87 papers on clinical outcome projects centered on neurological conditions. Dr. Van\nGompel works collaboratively with colleagues from Mayo Clinic’s Epilepsy and Neurophysiology lab, engaging in clinical work\nrelative to brain stimulation as a viable restorative therapy for epilepsy over current treatment methodologies.\n9\nCombined Dx + Tx\nPlatform Technology:\nOneRF® Diagnostic + Ablation Depth Electrode\nNeuroOne sEEG Electrode\nApplications: Advantages vs Ablative Lasers (Current Std. of Care)\n▪ Removes tumorous brain ▪ One procedure for diagnostic and therapeutic\ntissue expected to save time, money and to improve\npatient outcomes.\n▪ Creates lesions in the brain RF Generator\n▪ OneRF Ablation System leverages current w/ Temperature Sensing\nthat cause seizures\nNeuroOne sEEG technology\nCompetitors:\nAblation\n▪ Targeting early Q2 2023 FDA 510(k)\n▪ Medtronic Illustrative picture\nsubmission Advisory Board\n▪ Monteris Medical ▪ Uses well established RF energy to ablate\nDr. Daniel Couture Dr. Guy McKhann\ntissue.\nWake Forest Baptist Health New York Presbyterian Hospital\nColumbia University\n▪ Overcomes inherent laser drawbacks such as\nneed for MRI facility Dr. Gerald Grant Dr. Jamie Van Gompel\nDuke University Medical Center Mayo Clinic\nDr. Bob Gross\nEmory University\n10\nCombined Dx + Tx\nWW Market > $3B1\nSpinal Cord\nStimulation System\nPotential NeuroOne Advantages:\nCompetitive solutions\n▪ Ability to place paddle electrodes percutaneously\nPaddle and cylinder electrodes are\nplaced via two different procedures.\n▪ Lower power requirements = battery savings\nMajor vendors in this market include:\nMedtronic, Boston Scientific, Abbott.\n▪ Conformable design provides enhanced tissue coverage.\n▪ “Scalability” of electrodes offer greater precision of\ntargeted stimulation area\n▪ Successfully completed initial testing for 5 year use for\nrecording and stimulation\nNeuroOne’s solution\n▪ Advisory Board of leading anesthesiologists and\nTo percutaneously place a paddle like a\nneurosurgeons\ncylinder electrode to provide greater\nstimulation coverage with reduced\nbattery usage\n11\n1. Market Insights, Neurostimulation Devices. Published September 11, 2020, by Sophie Quraishi\nCombined Dx + Tx\nCurrently a $500M WW market\nwith potential of $6B2\nDeep Brain Stimulation System\nApplications\n▪ Parkinson’s Disease\nNeuroOne Advantages:\n▪ Epilepsy\n▪ Utilizes current electrode design\n▪ Essential Tremors\n▪ Our high-definition electrodes have been shown to detect micro seizures1 which\nCompetitors\nmay improve responsive stimulation algorithms\n▪ NeuroPace ▪ Medtronic\n▪ Additional technology applications may be suitable for drug delivery\n▪ Abbott ▪ Boston Scientific\n▪ Targeted stimulation for movement, psychiatric and cognitive disorders\n1. Bower R, et al. December 2017. Development of Polyimide electrodes for high-resolution intracranial EEG recordings. (Abst. 1.060) American Epilepsy Society. Washington, D.C.\n2. Market Insights, Neurostimulation Devices. Published September 11, 2020, by Sophie Quraishi\n12\nProduct Development Roadmap\nMarket\nOpportunity\nBillions\nDiagnostic Combined Dx + Tx\nDiagnostic1\nDx+Stimulation\n>$100 Million\nElectrode Market\ne\nz\nCurrently in\ni\nS OneRF® Development\nt Ablation\ne\nk\nr Targeting FDA 510(k)\na Less than 30 days\nearly Q2 submission;\nM\nEvo ® Depth potential launch by\nend of year\nElectrode\nCombination Dx + Tx\nLess than 30 Days Targeting Launch Direct or\nMulti-Billion Market2\nExpected Q1, 2023 Strategic\nEvo ® Cortical\nPartner\nElectrode Ablation\nSpinal cord stimulation\nDeep Brain Stimulation\nCommercial\nRights\nLeverage Common Technology Across All Our Products\n13 1) NeuroOne Estimate based on various research reports for US cortical and sEEG diagnostic market only\n2) Market opportunity derived from combination of diagnostic and therapeutic device TAMs (Total Addressable Markets)\nManagement Team\nMark Christianson\nCo-Founder, Business Development Director, Medical Sales Liaison\nDave Rosa In excess of 15 years of executive sales, sales management, marketing, and project\nmanagement experience with development stage companies. Prior to NeuroOne, Mr.\nPresident and Chief Executive Officer\nChristianson held the positions of North American Sales Manager for Cortec\nAn entrepreneur with three decades of experience in the medical device industry spanning a Corporation, a manufacturer of specialty chemical products, and Regional Sales\nvariety of technologies and products. In addition to CEO roles with early-stage medical device Manager for PMT Corporation, a leading manufacturer of products for neurosurgery,\ncompanies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific\northopedics and plastic surgery. He holds an accounting degree from Augsburg College.\nInc., and St. Jude Medical, where his responsibilities included marketing, product development and\nbusiness development. He has been named as an inventor on multiple medical device patents, has Hijaz Haris\nserved on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an\nMBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University. Vice-President of Marketing\nMr. Haris has more than 20 years of experience with Medtronic, the world’s largest\nRon McClurg\nMedical Device company. Most recently he led Global Marketing for Medtronic’s Brain\nChief Financial Officer Modulation business, where he helped refresh the Deep Brain Stimulation product\nMr. McClurg has over 30 years of financial leadership experience with private and public pipeline and led the business through a period of new competitive entries, new product\ncompanies. Prior to joining NeuroOne, Mr. McClurg was Chief Financial Officer of Incisive Surgical, launches, brand refresh, and various distribution partnerships. Prior to that Hijaz held\nInc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of various roles of increasing responsibility across multiple business segments (Cardiac\nWavecrest Corporation, a privately-held manufacturer of electronic test instruments. Mr. McClurg Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product\nalso served as Chief Financial Officer for several publicly-held companies, including Video Sentry\nand Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance).\nCorporation, Insignia Systems, Inc., and Orthomet, Inc. He began his career in public accounting\nwith Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business\nCamilo Diaz Botia\nAdministration degree in Accounting from the University of Wisconsin - Eau Claire.\nDirector of Electrode Development\nSteve Mertens\nDr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on\nChief Technology Officer the development of technologies for bidirectional communication with the nervous\nsystem. Most recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored\nPrior to joining NeuroOne, Mr. Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a\nthe process engineering team to deliver projects with unique microfabrication processes.\nprivately held lung denervation company developing minimally invasive products for obstructive\nlung diseases. Before that, he was a Senior Vice President of Research and Development for Under his direction, the team built and designed novel processes for integration of thin\nBoston Scientific, where he guided a wide range of technologies through product development for film neural probes with brain machine interface systems. Dr. Diaz-Botia earned a B.S. in\nthe cardiology, electrophysiology, and peripheral vascular markets. Mr. Mertens holds a Bachelor Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in\nof Science degree in Chemical Engineering from the University of Minnesota and a master’s Bioengineering from the joint program at the University of California Berkeley and the\ndegree in Business Administration from the University of St. Thomas.\nUniversity of California San Francisco.\nChad Wilhelmy\nVice President of Quality Control and Regulatory Affairs\nChad joined NeuroOne with 20 years of medical device experience developing,\nimplementing, and leading quality management systems. Prior to joining NeuroOne, he\nheld top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine\nHeart as the Senior Director of Quality. He has driven quality strategies from early-stage\ndevelopment to commercial distribution with both the FDA and Notified Body. Chad\nearned a Bachelor of Science degree from the University of Wisconsin - Stout in Engineering\n14\nTechnology with an emphasis in Quality.\nScientific Advisory Board\nGreg Worrell Bob Gross\nMD PhD, Chairman of the Scientific Advisory Board MD, PhD\nMBNA Bowman Chair & Professor Department of Neurosurgery, Emory\nWorld renowned neurologist at Mayo Clinic. Recognized by the American\nUniversity School of Medicine. Faculty in Biomedical Engineering at\nEpilepsy Society (AES), the American Academy of Neurology (AAN), the\nGeorgia Institute of Technology, Biological and Biomedical Sciences, and\nAmerican Neurological Association (ANA), and the Citizens United in\nCenter for Neurodegenerative Disease at Emory University. He\nResearch for Epilepsy (CURE) Foundation for his contributions to the field\npreviously served as President of the American Society for Stereotactic\nof epilepsy research. Dr. Worrell is a frequent keynote speaker at\nand Functional Neurosurgery and Section Editor of Neurosurgery\nneurology conferences and has published 90 papers.\n(journal). He has published more than 270 articles, having been cited\n15,660 times, and has co-edited 2 textbooks.\nJamie Van Gompel\nJustin Williams\nMD\nPhD\nNeurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing\nDepartment Chair and Vilas Distinguished Achievement Professor at\nminimally invasive techniques. Since 2008, Dr. Van Gompel has authored or co-\nUniversity of Wisconsin. Dr. Williams is credited with multiple\nauthored 87 papers on clinical outcome projects centered on neurological\npublications, patents, and research in the field of thin-film electrodes\nconditions. Dr. Van Gompel works collaboratively with colleagues from Mayo\nfor neurological recording, ablation, and stimulation.\nClinic’s Epilepsy and Neurophysiology lab, engaging in clinical work relative to\nbrain stimulation as a viable restorative therapy for epilepsy over current\ntreatment methodologies.\nKip Ludwig\nPhD\nGreg Esper\nMD, MBA Dr. Ludwig is the Co-Director of the Wisconsin Institute for Translational\nNeuroengineering (WITNe) and leads the Ludwig Laboratory at the University of\nAssociate Professor, Vice-President of Clinical Affairs, and Director of New\nWisconsin within the WITNe structure. The primary focus of his lab is\nCare Models in the Neurology Department at Emory University. Vice Chair\ndeveloping next-generation neuromodulation therapies that use minimally\nof the Medical Economics and Management Committee for the American\ninvasive strategies to hack the nervous system to treat circuit dysfunction and\nAcademy of Neurology (AAN). Dr. Esper was Chair of the Navigating Health\ndeliver biomolecules to target areas with unprecedented precision. Prior to\nReform Task Force for the AAN in 2012.\nWisconsin Dr. Ludwig served as the Program Director for Neural Engineering at\nthe National Institutes of Health.\n15\nFinancial Information\nNASDAQ: NMTC Financial Data\nPrice:1 $1.61\n90-Day Price Range:1 $1. 17 - $2.18\nDaily Volume – Last 30 Day Average: 1 170,787\nMarket Capitalization:1 $27.2 Million\nShares Outstanding:1 16.9 Million\nShares in Float:1 ~ 13.7 Million\nWarrants:1 6.8 Million (WAEP = $6.00)\nStock Options:1 1.4 Million (WAEP = $5.02)\n1 As of March 31, 2023\n16\nKey Takeaways\nPositioned to Create Shareholder Value Anticipated Catalysts & Milestones\nKey Partnerships:\n▪ Substantial market opportunity ▪ Zimmer launch of EVO® sEEG diagnostic\nelectrodes in Q1 2023; first two of multiple\n▪ Disruptive, patented technologies\norders recently shipped\n▪ Two FDA cleared electrodes with established\n▪ FDA submission of 510k for OneRF® Ablation\nreimbursement; others close to FDA submission or\nSystem in Q2 2023\ncompletion of development\n▪ Journal publication on OneRF® Ablation System\n▪ Platform technology potential for multiple\npreclinical study\napplications:\n▪ Advancement of OneRF® commercial strategy\n▪ Mayo and Cleveland Clinic have conducted\npreclinical studies, which have produced promising\n▪ Potential for additional partnerships to leverage\nresults utilizing our devices in humans and/or\nNeuroOne’s core technology\nanimals\n▪ Pipeline progress on spinal cord/brain\n▪ Experienced Management Team, Advisory Boards,\nstimulation electrode\nand Board of Directors\n▪ Exploration of new indications for platform\ntechnology (ie Mental health disorders such as\ndepression, OCD, substance abuse)\n17\nThank You\nDave Rosa\nChief Executive Officer\n18"
        },
        {
          "title": "Spring 24’ Company Update",
          "url": "https://storage.googleapis.com/neuroone-1156-4b1gd/NMTC-Fact-Sheet-Spring-24.pdf",
          "content": "FACT SHEET\nSpring 2024\nNasdaq: NMTC\nnmtc1.com\nAdvancing Neuroscience.\nNeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care\noptions and outcomes for patients suffering from neurological disorders. NeuroOne’s robust product suite offers acute\ndiagnostic neurology and chronic treatment solutions for epilepsy, Parkinson’s disease, dystonia, essential tremors, and\nchronic pain due to failed back surgeries. NeuroOne markets a minimally invasive and high-definition/high-precision\nelectrode technology platform with two FDA-cleared product families: Evo® Cortical Electrodes and Evo® sEEG\nElectrodes. These electrodes offer the potential to reduce the number of hospitalizations and surgical procedures,\nlower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions such as EEG\nrecording and tissue ablation and/or chronic stimulation. NeuroOne recently received FDA-clearance for its third product\nfamily, OneRF®, a novel combination recording and radiofrequency (RF) ablation device. The Company is engaged\nin research and development for drug delivery and spinal cord stimulation (SCS) programs and is exploring potential\napplications of its medical technology with artificial intelligence.\nKey Investment Considerations\n• Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology\ninitially developed in collaboration with Mayo Clinic, a shareholder of the Company.\n• First-to-market combination ablation technology; indication for both recording electrical activity and ablating\nnervous tissue.\n• Strategic collaboration with Zimmer Biomet (NYSE:ZBH, ~$25B mkt cap) for exclusive commercialization and\ndistribution of EVO® diagnostic electrodes; payments of $5.5 million received to date.\n• Potential to penetrate large disease populations and markets: epilepsy ($1B+), Parkinson’s disease ($5B+), and\nSCS ($10B+); licensing potential for applications in multiple related neurological disorders.\n• Multi-billion market opportunity for combination devices; potential for technology adaptation utilizing artificial\nintelligence.\n• Leadership with deep expertise in medical device technology, marketing, and business development; world-class\nboard of directors; esteemed scientific and physician advisory boards.\n• Ample capital resources to support upcoming commercial and development catalysts.\nKey Partnerships\nZimmer Biomet Agreement\nMayo Clinic Partnership\n Worldwide leader in orthopedics and  Mayo Clinic partnership with NeuroOne began in 2014\nrobotic technology used in minimally  Mayo Clinic began testing Evo® technology in pre-\ninvasive neurosurgeries\nclinical models and clinical research in 2015\n Exclusive development and distribution  First commercial human use of Evo® Cortical\nagreement since 2020; $5.5 million\nElectrodes performed at Mayo Clinic in November\nin licensing and milestone payments\n2020\nreceived  Mayo Clinic leading neurologist Dr. Greg Worrell chairs\n Evo® sEEG electrode product line complementary to\nNeuroOne Scientific Advisory Board\nZimmer’s ROSA ONE® Brain platform\nFiscal Year 2024 Potential Catalysts\n• Evo® sEEG: revenue expected to increase with addition of new accounts by Zimmer Biomet and commercial\nlaunch of the OneRF™ Ablation System.\n• OneRF™ Ablation System: limited commercial launch targeted for second calendar quarter of 2024.\n• Exploration of additional strategic partnerships that could leverage core high-resolution, thin-film electrode\ntechnology.\n• Exploration of new indications such as motor function, hypertension, high blood pressure, depression, and pain.\nMarket Snapshot\nShare Price 52-Wk. Range Avg. Vol. Shares O/S Market Cap\n$1.38 (3/4/24) $0.85 - $2.07 210K 25.9M $35.7M\nNeuroOne Medical Technologies Corporation | 7599 Anagram Drive Eden Prairie, MN 55344\nInvestor Relations Contact | 800-631-4030 | ir@nmtc1.com\nPrice and volume quotes from Yahoo! Finance\nEvo® Cortical Electrode* (less than 30-day use)\nThin-film electrode for the diagnosis of various neurological conditions. Evo’s high-definition, minimally invasive\ntechnology delivers major advantages over widely used legacy silicone-based electrodes.\n• 7 times thinner and 8 times lighter than typical silicone electrodes1\n• Reduced artifact and improved signal quality2\n• Reduced inflammation based on published testing by Mayo Clinic3\nEvo® sEEG Electrode* (less than 30-day use)\nStereoelectroencephalography recording, spinal cord stimulation, brain stimulation and ablation solutions.\nThe first clinical case use was performed intraoperatively by Dr. Robert Gross, Emory University for brain\nmapping at the subsurface level of the brain.\n• Less invasive – reduced risk of brain plunge, may require fewer brain insertions\n• Improved signal quality vs. other devices1\n• Proven implant accuracy1\n• Automated manufacturing, precise and consistent quality1\n*Caution U.S. Federal law restricts this device to sale by, or on the order of, a physician.\n1NeuroOne data on file 2Bower R., et al. December 2017. Multi-Resolution intracranial EEG rodent recording system. (Abst. 2.062) 2017. American Epilepsy Society 3Worrell,\nG. et. al. December 2019. Commercial Scale Production of Thin-Film electrode arrays for Clinical Intracranial EEG. (Abst. 1.154), 2019. American Epilepsy Society)\nOneRF™ Ablation System (510(k) application under FDA review)\nUtilizes existing implanted sEEG diagnostic electrodes for RF ablation in nervous (brain) tissue to\ncreate tissue lesion(s). Safer and less expensive combination electrode, intended to improve patient\noutcomes, reduce procedures, and lower overall treatment cost.\n• Less discomfort to patient\n• More efficient for surgeon\n• Potentially better pain targeting\nInitial Target Markets\nEpilepsy — caused by conditions that affect the brain: stroke, brain tumor, traumatic brain injury, and central nervous\nsystem infections. Estimated $28B in annual costs.1\nBrain ablation — surgical removal of harmful brain tissue and tumors. Estimated $100M+ global market, growing rapidly.\nChronic back pain (CBP) — caused by an estimated 80,000+ “failed” back surgeries per year in the U.S.2; prevalence of\n3%+ in U.S. adult population. Estimated $187B in two-year direct and indirect costs.3\nParkinson’s disease — disorder of the central nervous system caused by loss of brain cells. Estimated $52B in annual\ndirect and indirect costs.4\n1AJMC: Examining the Economic Impact and Implications of Epilepsy 2NIH: Comparison among pain, depression, and quality of life. . . 3University of Texas Libraries: The\neconomic burden of chronic back pain... 4Parkinson’s Foundation Statistics\nLeadership\nDave Rosa, President and CEO: Three decades of experience in the medical device industry; CEO roles with early-\nstage companies and senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical.\nRon McClurg, CFO: 30 years of financial leadership experience; CFO at Incisive Surgical, Wavecrest Corporation, Video\nSentry Corporation, Insignia Systems, and Orthomet.\nChris Volker, COO: 20 years of medical device industry experience; senior leadership roles with Cardiovascular Systems\nand St. Jude Medical. Began his career in healthcare and technology investment banking.\nMark Christianson, Co-Founder, Business Development Director, Medical Sales Liaison: 15 years of executive sales,\nsales management, marketing, and project management experience with development stage companies.\nSteve Mertens, CTO: SVP of R&D and Operations at Nuvaira; SVP of R&D for Boston Scientific.\nHijaz Haris, VP of Marketing: 20 years of experience with Medtronic, the world’s largest medical device company.\nCamilo Diaz Botia, Director of Electrode Development: Experienced neuroengineer; process engineering team leader\nfor brain-computer interface technology at Neuralink Corp., founded by Elon Musk.\nChad Wilhelmy, VP Quality and Regulatory: 20 years of experience including leadership role at HLT, Inc.\nForward-Looking Statements: This fact sheet contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities\nExchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this fact sheet may be a forward–looking statement that reflects NeuroOne’s current views\nabout future events. Forward–looking statements may include statements regarding the development of the Company’s electrode technology program, applications for, or receipt of, regulatory\nclearance, the timing and extent of product launch and commercialization of our technology, clinical and pre-clinical testing, business strategy, market size, potential growth opportunities, future\noperations, future efficiencies, and other financial and operating information. Our actual future results may be materially different from what we expect due to known and unknown risks, uncertainties and\nother factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements,\nincluding risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of ourtechnology; whether due to supply chain disruptions and the impact of\nCOVID-19, or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s\ncapital requirements to achieve its business objectives and ability to raiseadditional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology;\nuncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated\nthe size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property\nrights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking\nstatements speak only as of the date of this fact sheet and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes\navailable in the future."
        }
      ]
    }
  ]
}